-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
Latest News
-
September 2026: This month in Huntington’s disease research
September brought progress across the HD research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in Huntington’s disease research.
-
Is Huntington’s disease twice as common as we thought?
New data suggest there may be twice as many people with HD symptoms as previously thought – and even more at risk
-
Two large HD observational studies – COHORT and Registry – merge to create ENROLL-HD
Merger of two major Huntington’s Disease observational trials creates ENROLL-HD
-
Huntexil for symptoms of Huntington's disease: where are we now?
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
-
Minocycline: the end of the road?
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
-
TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers
HDBuzz Trial Tracker
Show 10 more Show less
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
